The role of RAS modification for primary and secondary stroke prevention.

Clinical trial results indicate that the choice of antihypertensive agent can be a determinant of stroke protection, independent of blood pressure (BP) reduction. Angiotensin-converting enzyme inhibitors (ACE-Is) are effective for BP control and stroke protection, but their use may be limited by patient tolerability. Angiotensin receptor blockers appear to provide similar BP control compared with ACE-Is and may also offer the clinician the added benefit of primary and secondary stroke prevention, with the potential for fewer tolerability issues.
AuthorsDan J Fintel
JournalPostgraduate medicine (Postgrad Med) Vol. 121 Issue 4 Pg. 115-22 (Jul 2009) ISSN: 1941-9260 [Electronic] United States
PMID19641277 (Publication Type: Journal Article, Review)
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Angiotensin II Type 1 Receptor Blockers (therapeutic use)
  • Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
  • Antihypertensive Agents (therapeutic use)
  • Blood Pressure
  • Humans
  • Renin-Angiotensin System (physiology)
  • Risk Factors
  • Stroke (etiology, physiopathology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: